For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Morgan Stanley raised the firm’s price target on Johnson & Johnson to $169 from $164 and keeps an Equal Weight rating on the shares after ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an ...